Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 8,509 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Control to Boost Physical Activity Adherence

NCT06338774
View directory record Official record
Conditions
Physical Inactivity
Interventions
Cognitive training, Exercise
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

NCT00659750
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Encinitas, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Not applicable Interventional

Ongoing Tai Chi Training for Children With ADHD

NCT03434509
View directory record Official record
Conditions
ADHD
Interventions
Continuous Tai Chi and Mindful Movement classes
Other
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years to 15 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 2 Interventional

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00072709
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
TCH346
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 22, 2026, 4:32 PM EDT
Not listed Phase 2 Interventional

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

NCT04296864
View directory record Official record
Conditions
Atopic Keratoconjunctivitis
Interventions
Dupilumab
Drug
Lead sponsor
Andover Eye Associates
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Littleton, Colorado • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 22, 2026, 4:32 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)

NCT05251909
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

NCT02040298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

NCT01272232
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Not applicable Interventional

Family Routines Enhancing Adolescent Diabetes by Optimizing Management

NCT02974309
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sleep Extension, Routine
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
10 Years to 17 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 22, 2026, 4:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease

NCT00026598
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

MRI Neurofeedback and Brain Circuits Related to Motivation in Healthy Participants

NCT05929898
View directory record Official record
Conditions
Motivation, Memory, Self-regulation
Interventions
Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT03310463
View directory record Official record
Conditions
Acinetobacter Baumannii Infection
Interventions
ETX2514SUL
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04211363
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Roflumilast 0.3% cream, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mindfulness and Neural Cardiovascular Control in Humans

NCT03626363
View directory record Official record
Conditions
Elevated Blood Pressure
Interventions
Stress Management
Behavioral
Lead sponsor
Michigan Technological University
Other
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Hammond, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

CP-690-550 Ointment For Chronic Plaque Psoriasis

NCT01246583
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2, Vehicle 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Mobile, Alabama • Los Angeles, California • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 22, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Social Regulation of Threat-related Vigilance and Arousal

NCT05558527
View directory record Official record
Conditions
Psychological Trauma, Historical, Discrimination, Racial, Emotion Regulation, Social Interaction, Hypervigilance, Anxiety
Interventions
social support
Behavioral
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

NCT00663169
View directory record Official record
Conditions
Arthritis, Gouty
Interventions
canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone
Biological · Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 22, 2026, 4:32 PM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

NCT06776783
View directory record Official record
Conditions
Respiratory Distress Syndrome, Pre-term Infants
Interventions
APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control
Combination Product · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
18
States / cities
Little Rock, Arkansas • La Jolla, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Terminated Phase 3 Interventional Results available

Topiramate in the Treatment of Pathological Gambling

NCT00245583
View directory record Official record
Conditions
Pathological Gambling
Interventions
Topiramate, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 22, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Family-Centered Implementation of Parent Training for Autistic Toddlers in Early Intervention

NCT07471594
View directory record Official record
Conditions
Autism
Interventions
Parent Training
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
12 Months to 36 Months
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

NCT00681356
View directory record Official record
Conditions
Total Knee Arthroplasty (Replacement)
Interventions
4975, 15 and 5 mg, Placebo Comparator, 4975 - 5 mg
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 22, 2026, 4:32 PM EDT
Completed No phase listed Observational

Identification of Inpatients at Risk for Poor Glycemic Control

NCT01043042
View directory record Official record
Conditions
Hypoglycemia, Hyperglycemia
Interventions
No interventions will be used in this study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
33,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 22, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional

The Erector Spinae Plane Block For Gastrointestinal Malignancy Pain Treatment (EGIPT)

NCT07211386
View directory record Official record
Conditions
Gastrointestinal Malignancy, Pain Control
Interventions
Erector Spinae Plane Block
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 22, 2026, 4:32 PM EDT